132 related articles for article (PubMed ID: 7835621)
1. Enhancement of gastric mucus phospholipid secretion by an antiulcer agent, ebrotidine.
Slomiany BL; Piotrowski E; Piotrowski J; Zirvi KA; Liau YH; Murty VL; Slomiany A
Gen Pharmacol; 1994 Sep; 25(5):1033-7. PubMed ID: 7835621
[TBL] [Abstract][Full Text] [Related]
2. Effect of ebrotidine on the synthesis and secretion of gastric sulfomucin.
Slomiany BL; Lopez RA; Liau YH; Slomiany A
Gen Pharmacol; 1993 May; 24(3):611-7. PubMed ID: 8365641
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and secretion of gastric sulfomucin in the presence of ebrotidine, a new antiulcer agent.
Slomiany BL; Lopez RA; Slomiany A
Biochem Int; 1992 Dec; 28(4):665-74. PubMed ID: 1482403
[TBL] [Abstract][Full Text] [Related]
4. Gastroprotective properties of ebrotidine. A review.
Slomiany BL; Piotrowski J; Slomiany A
Arzneimittelforschung; 1997 Apr; 47(4A):459-67. PubMed ID: 9205744
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of ebrotidine protection against gastric mucosal injury induced by ethanol.
Slomiany BL; Piotrowski J; Murty VL; Slomiany A
Gen Pharmacol; 1992 Jul; 23(4):719-27. PubMed ID: 1356875
[TBL] [Abstract][Full Text] [Related]
6. Ebrotidine--a new H2-receptor antagonist with mucosal strengthening activity.
Piotrowski J; Yamaki K; Morita M; Slomiany A; Slomiany BL
Biochem Int; 1992 Mar; 26(4):659-67. PubMed ID: 1351724
[TBL] [Abstract][Full Text] [Related]
7. Studies on the cytoprotective and antisecretory activity of ebrotidine. A review.
Konturek PC; Brzozowski T; Konturek SI; Márquez M; Torres J; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):578-89. PubMed ID: 9205769
[TBL] [Abstract][Full Text] [Related]
8. Induction of tumor necrosis factor-alpha and apoptosis in gastric mucosal injury by indomethacin: effect of omeprazole and ebrotidine.
Slomiany BL; Piotrowski J; Slomiany A
Scand J Gastroenterol; 1997 Jul; 32(7):638-42. PubMed ID: 9246701
[TBL] [Abstract][Full Text] [Related]
9. Regulation of gastric mucosal calcium channel activity by an antiulcer agent, ebrotidine.
Slomiany BL; Liu J; Piotrowski J; Czajkowski A; Yotsumoto F; Slomiany A
J Physiol Pharmacol; 1994 Mar; 45(1):121-31. PubMed ID: 7519082
[TBL] [Abstract][Full Text] [Related]
10. Gastric mucosal EGF and PDGF receptor expression with ulcer healing by ebrotidine.
Slomiany BL; Piotrowski J; Czajkowski A; Yotsumoto F; Slomiany A
Am J Gastroenterol; 1994 Jun; 89(6):894-7. PubMed ID: 8198101
[TBL] [Abstract][Full Text] [Related]
11. Histamine H2-receptor antagonist action of ebrotidine. Effects on gastric acid secretion, gastrin levels and NSAID-induced gastrotoxicity in the rat.
Palop D; Agut J; Márquez M; Conejo L; Sacristán A; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):439-46. PubMed ID: 9205740
[TBL] [Abstract][Full Text] [Related]
12. Gastroprotective and ulcer-healing activities of a new H2-receptor antagonist: ebrotidine.
Brzozowski T; Majka J; Konturek SJ
Digestion; 1992; 51(1):27-36. PubMed ID: 1353465
[TBL] [Abstract][Full Text] [Related]
13. Effect of ebrotidine on ethanol-induced gastric mucosal damage in the rat. Comparative study with other H2-receptor antagonists.
Palop D; Romero A; Villamayor F; Conejo L; Sacristán A; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):450-4. PubMed ID: 9205742
[TBL] [Abstract][Full Text] [Related]
14. Effect of ebrotidine on gastric mucosal inflammatory responses to Helicobacter pylori lipopolysaccharide.
Slomiany BL; Piotrowski J; Slomiany A
J Physiol Pharmacol; 1999 Sep; 50(3):391-404. PubMed ID: 10574469
[TBL] [Abstract][Full Text] [Related]
15. Anti-Helicobacter pylori activities of ebrotidine. A review of biochemical and animal experimental studies and data.
Slomiany BL; Piotrowski J; Slomiany A
Arzneimittelforschung; 1997 Apr; 47(4A):475-82. PubMed ID: 9205747
[TBL] [Abstract][Full Text] [Related]
16. Double-blind crossover study of ranitidine and ebrotidine in gastro-esophageal reflux disease.
Sito E; Thor PJ; M[aczka M; Lorens K; Konturek SJ; Maj A
J Physiol Pharmacol; 1993 Sep; 44(3):259-72. PubMed ID: 8241527
[TBL] [Abstract][Full Text] [Related]
17. Prevention and healing of experimental indomethacin-induced gastric lesions: effects of ebrotidine, omeprazole and ranitidine.
Arroyo MT; Lanas A; Sáinz R
Eur J Gastroenterol Hepatol; 2000 Mar; 12(3):313-8. PubMed ID: 10750652
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of Helicobacter pylori urease activity by ebrotidine.
Piotrowski J; Slomiany A; Slomiany BL
Biochem Mol Biol Int; 1995 Oct; 37(2):247-53. PubMed ID: 8673007
[TBL] [Abstract][Full Text] [Related]
19. Enhancement in the protective qualities of gastric mucus by ebrotidine during duodenal ulcer healing.
Slomiany BL; Piotrowski J; Majka J; Czajkowski A; Slomiany A; Gabryelewicz A
Gen Pharmacol; 1995 Sep; 26(5):1039-44. PubMed ID: 7557247
[TBL] [Abstract][Full Text] [Related]
20. Endothelin-1, interleukin-4 and nitric oxide synthase modulators of gastric mucosal injury by indomethacin: effect of antiulcer agents.
Slomiany BL; Piotrowski J; Slomiany A
J Physiol Pharmacol; 1999 Jun; 50(2):197-210. PubMed ID: 10424717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
